Seeking Alpha

NuPathe (PATH) intends to reduce its workforce by half in order to cut expenses and focus on...

NuPathe (PATH) intends to reduce its workforce by half in order to cut expenses and focus on receiving approval for its NP101 migraine patch. The company, which has almost 40 employees, will also lower marketing costs, and postpone the application for its NP202 drug for schizophrenia and bipolar disorder until it finds a partner. NuPathe is trying to raise $28M in financing. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs